Tolero Pharmaceuticals Submits Investigational New Drug Application for Experimental PKM2 Activator TP-1454
Retrieved on:
星期二, 五月 19, 2020
SALT LAKE CITY, Utah, May 19, 2020 /PRNewswire/ --Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, TP-1454.
Key Points:
- SALT LAKE CITY, Utah, May 19, 2020 /PRNewswire/ --Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, TP-1454.
- "TP-1454 will be the first PKM2 activator to be tested in cancer patients, representing a novel mechanism that aims to target the underlying metabolics driving tumor growth and anti-cancer immune suppression.
- We look forward to building our understanding of the potential role of PKM2 activation in the treatment of solid tumors."
- TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator, that will be evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors.